Skip to content
Medical Health Aged Care

Emerging field of circadian medicine gets a boost with new global association

Monash University 2 mins read

World-leading experts in the emerging field of circadian medicine are proud to announce a new global association to further the science of sleep and other circadian rhythms, and take those findings into clinical practice.

The International Association of Circadian Health Clinics (IACHC) will bring together researchers and clinicians across the globe - including the USA, Asia, Europe and Australia - to develop evidence-based, personalised patient care centred around the circadian timing system.

Monash University Professor of Sleep and Circadian Medicine, Shantha Rajaratnam, said the association was a major step in advancing circadian-informed diagnosis and treatment for many disorders.

“Circadian processes affect every system in the body, and have an enormous impact on sleep, metabolism, mental health and progression of diseases such as cancer,” he said. “This association will advance and coordinate the emerging field of clinical circadian medicine to achieve significant impact on healthcare and benefit to patients.”

Researchers from Monash University’s Turner Institute for Brain and Mental Health and School of Psychological Sciences have formed a working group to steer the association’s vision, with colleagues at Harvard Medical School (including Brigham and Women’s Hospital and Massachusetts General Hospital), Northwestern University, University of Colorado, Brown University, Canada’s McGill University, the Psychiatric Hospital of the University of Basel in Switzerland, the University of Bergen in Norway, and Charité Universitätsmedizin Berlin.

The association will offer members:


Research and innovation: research initiatives, encourage innovation, and drive technological advancements in circadian medicine.

Educational resources: programs, webinars, workshops, and conferences to foster continuous learning and professional development.

Advocacy and representation: a unified voice for circadian health professionals and clinicians, promoting industry best practices, and influencing policy decisions.

Networking opportunities: access to a diverse community of research and clinical professionals, to forge valuable connections, exchange ideas, and build partnerships.

Membership of the International Association of Circadian Health Clinics is open to professionals, organisations, and stakeholders across the sleep and circadian medicine field. Visit https://circadianhealthclinics.com/ 

For media enquiries please contact:

Monash University

Cheryl Critchley - Communications Manager (medical)
E: [email protected] 

T: +61 (0) 418 312 596

For more Monash media stories, visit our news and events site  


For general media enquiries please contact:
Monash Media
E: [email protected]
T: +61 (0) 3 9903 4840

 

***ENDS***

 

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 17:10
Galderma Group AG

Galderma Welcomes Increased Equity Investment From L’Oréal

L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.